These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 16815231)

  • 1. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.
    Pai AB; Pai MP
    Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of gram-positive coccal bacteremia and hemodialysis.
    Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
    Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections.
    Del Pozo JL; Alonso M; Serrera A; Hernaez S; Aguinaga A; Leiva J
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):208-12. PubMed ID: 19026506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients.
    Sader HS; Fritsche TR; Jones RN
    Int J Infect Dis; 2009 Mar; 13(2):291-5. PubMed ID: 18938097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antibiotic agents for bloodstream infections.
    Vergidis PI; Falagas ME
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with daptomycin: bacteraemia and endocarditis.
    Levine DP
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer developments in the treatment of Gram-positive infections.
    Koomanachai P; Crandon JL; Nicolau DP
    Expert Opin Pharmacother; 2009 Dec; 10(17):2829-43. PubMed ID: 19929705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and management of Gram-positive bacteraemia.
    Cervera C; Almela M; Martínez-Martínez JA; Moreno A; Miró JM
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S26-30. PubMed ID: 19931813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
    Johnson A
    Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microbiologic study of bacteremia and fungemia in chronic hemodialysis patients].
    Zárate MS; Jordá Vargas L; Lanza A; Relloso S; Díaz C; Smayevsky J
    Rev Argent Microbiol; 2005; 37(3):145-9. PubMed ID: 16323664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients.
    Ashour HM; el-Sharif A
    J Clin Oncol; 2007 Dec; 25(36):5763-9. PubMed ID: 18089873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.